Biovac’s EU-backed quasi-equity package and Brazil’s planned $1.2 billion vaccine PPP suggest that life-sciences are increasingly viewed as social infrastructure. But even vaccine sovereignty is hard to bank without public risk-sharing, demand visibility and unusually credible developers.